Rhelion Life Sciences Corp. (CSE:RHEL)
Canada · Delayed Price · Currency is CAD 0.0300
-0.0025 (-7.69%)
Sep 18, 2026, 1:31 PM EST
Rhelion Life Sciences Revenue
Rhelion Life Sciences had revenue of 186.07K CAD in the quarter ending June 30, 2026, a decrease of -66.35%. This brings the company's revenue in the last twelve months to 3.83M, down -2.80% year-over-year. In the fiscal year ending March 31, 2026, Rhelion Life Sciences had annual revenue of 4.20M, down -15.15%.
Revenue (ttm)
3.83M
Revenue Growth
-2.80%
P/S Ratio
4.81
Revenue / Employee
n/a
Employees
n/a
Market Cap
18.42M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 4.20M | -749.01K | -15.15% |
| Mar 31, 2025 | 4.94M | 192.40K | 4.05% |
| Mar 31, 2024 | 4.75M | 802.31K | 20.31% |
| Mar 31, 2023 | 3.95M | 1.62M | 69.84% |
| Mar 31, 2022 | 2.33M | 2.21M | 1,995.96% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Ayr Wellness | 650.97M |
| FLUENT | 107.89M |
| Red White & Bloom Brands | 52.92M |
| GoGo AI Network | 3.98M |
| ReVolve Renewable Power | 3.82M |
| Luxxfolio Holdings | -5.11K |
Rhelion Life Sciences News
- 2 days ago - Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Signs Supply and Licensing Agreement with the Centre for Human Drug Research for PEX010 in a Study of Low and Medium Dose Psilocybin - Newsfile Corp
- 4 days ago - Rhelion Life Sciences Wholly Owned Subsidiary Filament Health Signs Supply and Licensing Agreement with the University of Southern California for PEX010 in a Trial for Psilocybin-Assisted Mindfulness Therapy - Newsfile Corp
- 5 days ago - Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health to Deliver Oral Comments at FDA Public Hearing on the Potential Future Therapeutic Use of Psychedelic Drugs - Newsfile Corp
- 9 days ago - Rhelion Life Sciences Announces Filament Health is Planning a Stability Program for IBEX011, Its Naturally Derived Ibogaine Drug Candidate - Newsfile Corp
- 11 days ago - Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Completes Shipment of PEX010 to Australia for University of Melbourne Trial of Psilocybin-Assisted Physiotherapy in Functional Neurological Disorder - Newsfile Corp
- 16 days ago - Rhelion Life Sciences Confirms Further Delivery of Filament Health's PEX010 to Germany's First Psilocybin Compassionate Use Program - Newsfile Corp
- 19 days ago - Rhelion Life Sciences Reports First Quarter 2027 Results - Newsfile Corp
- 19 days ago - Rhelion Life Sciences Registration statement: Q1 2027 - Filings